Contineum Therapeutics, Inc.
CTNM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CTNM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CTNM
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing internally-discovered small molecule inhibitors for neuroinflammation and immunology (NI&I) indications, with lead candidates PIPE-791 (LPA1R antagonist) and PIPE-307 (M1R antagonist) in early-stage clinical development [sec_mda · as of 2026-03-05].
Key risk: Clinical development risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for Contineum Therapeutics, Inc..
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing internally-discovered small molecule inhibitors for neuroinflammation and immunology (NI&I) indications, with lead candidates PIPE-791 (LPA1R antagonist) and PIPE-307 (M1R antagonist) in early-stage clinical development [sec_mda · as of 2026-03-05].
- Contineum's two clinical-stage drug candidates are PIPE-791 (LPA1R inhibitor for IPF, PrMS, chronic pain) and PIPE-307 (M1R antagonist for RRMS, MDD) [sec_mda · as of 2026-03-05].
- PIPE-307 is developed in collaboration with J&J; a Phase 2 VISTA trial in RRMS did not meet primary or secondary efficacy endpoints [sec_mda · as of 2026-03-05].
- The company submitted a global Phase 2 trial of PIPE-791 for IPF to ClinicalTrials.gov in December 2025 [sec · filed 2025-12-11].
- As of 2026-06-30, Contineum reported cash & equivalents of $14.7M, net income of -$15.2M, and shareholders' equity of $261.0M [sec].
- The company expects operating expenses to increase significantly as it continues development and seeks regulatory approvals [sec_mda · as of 2026-03-05].
What works
- PIPE-791 targets a clinically validated mechanism (LPA1R antagonism) in IPF, with preclinical data suggesting high bioavailability, low plasma protein binding, and long receptor residence time [sec_mda · as of 2026-03-05].
- PIPE-307 is described as the most advanced selective M1R antagonist in clinical development [sec_mda · as of 2026-03-05].
- The company has a collaboration with J&J for PIPE-307, which may provide development and financial support [sec_mda · as of 2026-03-05].
What to weigh
- Contineum is heavily dependent on the success of PIPE-791 and PIPE-307, both in early clinical stages, and neither may progress or receive regulatory approval [sec · filed 2026-04-30].
- The Phase 2 VISTA trial of PIPE-307 in RRMS did not meet its prespecified primary and secondary efficacy endpoints, and J&J has sole discretion on further development [sec_mda · as of 2026-03-05].
- The company has a limited cash position of $14.7M as of 2026-06-30, and expects operating expenses to increase, raising uncertainty about its ability to fund planned milestones [sec_mda · as of 2026-03-05].
- Contineum has a history of net losses and expects fluctuations in quarterly results depending on trial timing and scope [sec_mda · as of 2026-03-05].
From the filings
Quoted directly from source documents.
Contineum is heavily dependent on PIPE-791 and PIPE-307, both in early clinical development.
“the Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development, and neither of these drug candidates may progress through clinical development or receive regulatory approval”
SEC filings · April 30, 2026
PIPE-307 Phase 2 VISTA trial in RRMS did not meet primary or secondary efficacy endpoints.
“The trial did not meet its prespecified primary and secondary efficacy endpoints.”
SEC MD&A · March 5, 2026
PIPE-791 Phase 2 trial in IPF was submitted to ClinicalTrials.gov in December 2025.
“On December 8, 2025, the Company submitted the details of its global Phase 2 clinical trial of PIPE-791 to treat patients with idiopathic pulmonary fibrosis (IPF) to the ClinicalTrials.gov Protocol Registration and Results System (PRS).”
SEC filings · December 11, 2025
Contineum expects operating expenses to increase significantly.
“We expect our operating expenses to significantly increase as we continue to develop and seek regulatory approvals for our drug candidates”
SEC MD&A · March 5, 2026
Risks & what to watch (4)›
Key risks
- Clinical development risk — Both lead candidates are in early stages; failure to progress or gain approval would materially harm the company [sec · filed 2026-04-30].
- PIPE-307 efficacy failure — Phase 2 RRMS trial missed endpoints; J&J may discontinue development, leaving PIPE-307's future uncertain [sec_mda · as of 2026-03-05].
- Limited cash runway — Cash of $14.7M as of 2026-06-30 may be insufficient to fund planned operations and trials without additional financing [sec_mda · as of 2026-03-05].
- Dependence on collaboration — J&J has sole discretion over PIPE-307 development; company has limited control over its partnered program [sec_mda · as of 2026-03-05].
What to watch
- Initiation and enrollment of the Phase 2 trial of PIPE-791 in IPF, submitted to ClinicalTrials.gov in December 2025 [sec · filed 2025-12-11].
- J&J's decision on further development of PIPE-307 for RRMS, MDD, or other indications following the Phase 2 VISTA miss [sec_mda · as of 2026-03-05].
- Contineum's ability to secure additional financing given its $14.7M cash position and increasing operating expenses [sec_mda · as of 2026-03-05].
- Any updates on the deferred PIPE-791 PrMS program and potential new indications [sec_mda · as of 2026-03-05].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Contineum Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Contineum Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
59.3 months
D/E 0.04 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
0 buys · 13 sells (180d)
Runway
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 4.9%
- Days to cover
- 6.4
- Shares short
- 1,605,258
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CTNM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Contineum Therapeutics, Inc.?
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing internally-discovered small molecule inhibitors for neuroinflammation and immunology (NI&I) indications, with lead candidates PIPE-791 (LPA1R antagonist) and PIPE-307 (M1R antagonist) in early-stage clinical development [sec_mda · as of 2026-03-05].
What is Contineum Therapeutics, Inc.'s lead drug candidate?
Contineum Therapeutics, Inc.'s most advanced tracked candidate is PIPE-307 (Phase 2) for Chronic Osteoarthritis Pain.
Who is the CEO of Contineum Therapeutics, Inc.?
Mr. Carmine N. Stengone MBA, MS is the chief executive officer of Contineum Therapeutics, Inc. (CTNM).
Where is Contineum Therapeutics, Inc. headquartered?
Contineum Therapeutics, Inc. (CTNM) is headquartered in San Diego, CA, United States.
What therapeutic areas does Contineum Therapeutics, Inc. focus on?
Contineum Therapeutics, Inc. develops therapies across Respiratory, Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.